GlassScriptPhysician profile
Anezi E Bakken
NPI 1568444545
$3,107.33
in general payments reported to CMS, 2019-2025
22 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $663 · 2024: $915 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,008 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,008.33 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,326.32 | 2023-2025 | Rinvoq, Viberzi, Linzess |
| Janssen Biotech, INC. | $379.14 | 2023-2025 | Tremfya, Stelara |
| Pfizer INC. | $267.54 | 2023-2025 | |
| Genzyme Corporation | $191.22 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.62 | 2023-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $177.44 | 2023-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $100.75 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $80.17 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $77.50 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $57.10 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $45.84 | 2024-2025 | |
| Celgene Corporation | $38.90 | 2023-2024 | Zeposia |
| Mauna Kea Technologies, INC. | $31.70 | 2024 | |
| Aimmune Therapeutics, INC. | $29.60 | 2025 | Vowst |
| Ironwood Pharmaceuticals, INC | $27.55 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $26.21 | 2024 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $22.21 | 2025 | |
| Sandoz INC. | $19.28 | 2024 | |
| Novo Nordisk INC | $14.19 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $13.05 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anezi Bakken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.